RxDoctor Payments Data

Angel Feliciano, MD

General Practice · Delray Beach, FLNPI 1548256480

Payments from drug & device makers

$7,991in general payments, 2019–2025

Across 30 payments — averaging $266.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Amgen$312
  • Novartis$140
  • Valeritas, Inc.$110
  • Boston Scientific$73
  • Abbott$61
  • plus $76 from 4 others

What the payments were for

  • Speaking & faculty fees$6,08076%
  • Travel & lodging$5427%
  • Food & beverage$1,34917%
  • Education$200%

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,991 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$341,422
Medicare patients
1,147
Services billed
4,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$148,241
EliquisApixaban132$144,996
XareltoRivaroxaban118$107,312
MounjaroTirzepatide75$95,202
GenvoyaElviteg/Cob/Emtri/Tenof Alafen14$55,498
VascepaIcosapent Ethyl35$23,447
JardianceEmpagliflozin22$22,825
Repatha SyringeEvolocumab24$19,096
LinzessLinaclotide25$16,031
MyrbetriqMirabegron13$15,387
FarxigaDapagliflozin Propanediol12$13,024
Repatha SureclickEvolocumab13$12,344
RybelsusSemaglutide11$10,233
Breo ElliptaFluticasone/Vilanterol15$10,156
Atorvastatin Calcium858$7,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$144,996132 claims
Johnson & JohnsonXarelto$7,218$107,312118 claims
Boehringer IngelheimJardiance$15$22,82522 claims
AstraZenecaFarxiga$21$13,02412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →